NCT04970225Completed
Cystic Fibrosis Blood Neutrophils
Functional and Phenotypic Characteristics of Blood Neutrophils in Cystic Fibrosis
Source: ClinicalTrials.gov · Last updated 12 Sept 2025
Brief summary (registry, in English)
The purpose of this prospective study is to analyze function and phenotype of blood neutrophils in cystic fibrosis patients and the impact of Pseudomonas aeruginosa chronic infection, treatment with CFTR modulators and acute exacerbation on blood neutrophils phenotype and function.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 47 (actual)
- First submitted
- 17 Jan 2019
- Start date
- 8 Jul 2021
- Primary completion date
- 6 Apr 2023
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Cystic fibrosis
- NCT number
- NCT04970225
What you commit to
- Study type: Interventional
- Participants enrolled: 47
- From 8 Jul 2021 to the primary completion date, 6 Apr 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Involvement in an interventional research protocol in the previous 3 months if exclusion directive was given in this protocol.
Other
- Informed consent impossible to obtain
Who the study is looking for
- Patient over the age of 18 who is not under legal protection
- Patients with CF according to the diagnostic criteria of the Cystic Fibrosis Foundation including:
- 15 patients with severe mutation but not chronically infected with PA and not treated with lumacaftor / ivacaftor
- 15 patients homozygous phe508del, chronically infected with PA and not treated with lumacaftor / ivacaftor
- 15 patients homozygous phe508del, chronically infected with PA and treated with lumacaftor / ivacaftor
- 15 hospitalized patients for respiratory exacerbation
- 40 patients initiating Ivacaftor-Tezacaftor-Elexacaftor treatment.
- No change in baseline treatment for 15 days (including antibiotic treatment).
- Patient affiliated to a social security system
- Free, informed and written consent, dated and signed by the patient and the investigator, at the latest on the day of inclusion and before any action required by the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cochin hospital, AP-HP Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.